<DOC>
	<DOCNO>NCT02116361</DOCNO>
	<brief_summary>This study evaluate safety efficacy onabotulinumtoxinA ( BOTOXÂ® ) compare placebo treatment major depressive disorder ( MDD ) adult female .</brief_summary>
	<brief_title>OnabotulinumtoxinA Treatment Major Depressive Disorder Adult Females</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Moderate severe major depressive disorder Prior treatment botulinum toxin serotype reason Use antidepressant medication depression within 2 week study Diagnosis Myasthenia gravis , EatonLambert Syndrome , Amyotrophic Lateral Sclerosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>